Arterium Corporation launches a new product for endocrinology in Ukraine
Arterium Corporation launches Dimaryl, its new drug, on Ukrainian market. This is an antidiabetic drug to be used as a part of combination therapy for non-insulin-dependent type II diabetes. It contains glimepiride as an active pharmaceutical ingredient.
Glimepiride helps to release insulin from the pancreatic gland. This effect is based on an increase of responsiveness of pancreatic cells to the physiological glucose stimulus. In addition, glimepiride has pronounced extrapancreatic effects: it enhances sensitivity of peripheral (muscle and fat) tissue to insulin and decreases glucose production by the liver.
Convenient dosage form and administration schedule – Dimaryl 2 mg, 3 mg or 4 mg, a scored tablet to be taken once daily – contribute to high compliance meaning that a patient takes the drug exactly as prescribed. With once daily administration, diabetic patients achieve good metabolic control for 24 hours.
Glimepiride molecule has been known in clinical practice for a long time: it has been used in world medical practice since 1995 and is widely prescribed as a part of combination therapy for type II diabetes.
Market launch of Dimaryl opens a great opportunity for endocrinologists – they now can prescribe a high-quality glimepiride product with established bioequivalence profile at an affordable price.
This is a brief summary of product characteristics. For full information, please refer to the patient leaflet.
This website is intended for medical and pharmaceutical experts only.